NKTR

Nektar Therapeutics
CAPPED RATING

Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company\'s research and development activities involve small-molecule drugs, and peptides.

Nektar Therapeutics (NKTR) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D). The rating has held at C for 9 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B-
Factor Score 2.9 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
D
Factor Score 1.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.6
EV / EBITDA -5.6
Rev Growth YoY -9.3%
Gross Margin N/M
Price Return 3M -49.0%
Price Return 12M -37.1%
Catalyst Signal 0.00
Market Cap $1.3B
TTM Revenue $54.6M
Price / Sales 23.3
ROE -35.8%

Historical Factor Score Progression

Held C for 9 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (2.9) D+ (1.8) C+ (2.6) D (1.2) C+ (2.6) C (2.2)
2026-11-06 B- (2.9) D+ (1.8) C+ (2.6) D- (1.1) C+ (2.7) C (2.2)
2026-10-30 B- (2.9) D+ (1.8) C+ (2.7) D+ (1.7) C+ (2.7) C (2.3)
2026-10-23 B- (2.9) D+ (1.8) C+ (2.7) D (1.5) C+ (2.6) C (2.3)
2026-10-16 B- (2.9) D+ (1.8) C+ (2.7) C- (1.9) C+ (2.6) C (2.4)
Page 1 of 8
…